{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:20:13Z","timestamp":1790277613465,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prrv.2026.05.009","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:03:18Z","timestamp":1780718598000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["How to monitor response to biologics in children with severe asthma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8055-7690","authenticated-orcid":false,"given":"Latika","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Arigliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2026.05.009_b0005","unstructured":"GINA. Global strategy for asthma management and prevention 2024; Available from: https:\/\/ginasthma.org\/2024-report\/."},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0010","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00765-2017","article-title":"\u201cI have lost in every facet of my life\u201d: the hidden burden of severe asthma","volume":"50","author":"Foster","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2026.05.009_b0015","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fped.2018.00186","article-title":"The burden of pediatric asthma","volume":"6","author":"Ferrante","year":"2018","journal-title":"Front Pediatr"},{"issue":"11","key":"10.1016\/j.prrv.2026.05.009_b0020","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/02770903.2020.1802747","article-title":"The economic burden of severe asthma in children: a comprehensive study","volume":"58","author":"Pamuk","year":"2021","journal-title":"J Asthma"},{"issue":"9","key":"10.1016\/j.prrv.2026.05.009_b0025","first-page":"724","article-title":"Direct and indirect costs of paediatric asthma in the UK: a cost analysis","volume":"109","author":"Kennedy","year":"2024","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.prrv.2026.05.009_b0030","article-title":"Choosing biologic therapy in children with severe asthma","author":"Gupta","year":"2025","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0035","doi-asserted-by":"crossref","first-page":"00381","DOI":"10.1183\/23120541.00381-2021","article-title":"Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy","volume":"7","author":"Golebski","year":"2021","journal-title":"ERJ Open Research"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0040","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/all.70031","article-title":"Predictors of response to biologics for severe asthma: a systematic review and meta-analysis","volume":"81","author":"Rattu","year":"2026","journal-title":"Allergy"},{"issue":"3, Supplement","key":"10.1016\/j.prrv.2026.05.009_b0045","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaci.2025.05.034","article-title":"Current data on biologics: evaluating clinical remission in asthma","volume":"156","author":"Pavord","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.prrv.2026.05.009_b0050","unstructured":"Guidance, N. Dupilumab for treating severe asthma with type 2 inflammation 2021; Available from: https:\/\/www.nice.org.uk\/guidance\/ta751."},{"key":"10.1016\/j.prrv.2026.05.009_b0055","unstructured":"excellence, N.I.o.H.a.c. Mepolizumab for treating severe eosinophilic asthma (NICE technology appraisal guidance Ta671). 2021; Available from: https:\/\/www.nice.org.uk\/guidance\/ta671."},{"key":"10.1016\/j.prrv.2026.05.009_b0060","unstructured":"NICE. Tezepelumab for treating severe asthma. 2023; Available from: https:\/\/www.nice.org.uk\/guidance\/ta880\/chapter\/1-Recommendations."},{"key":"10.1016\/j.prrv.2026.05.009_b0065","unstructured":"NICE. Omalizumab for severe persistent allergic asthma. 2013; Available from: https:\/\/www.nice.org.uk\/guidance\/ta278\/resources\/omalizumab-for-severe-persistent-allergic-asthma-pdf-425322541#:\u223c:text=You%20(or%20your%20child)%20should,you%20(or%20your%20child)%3A&text=have%20been%20diagnosed%20with%20a,courses%20in%20the%20last%20year)."},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0070","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00634-2017","article-title":"Severe eosinophilic asthma: a roadmap to consensus","volume":"49","author":"Buhl","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0075","article-title":"Definitions of non-response and response to biological therapy for severe asthma: a systematic review","volume":"9","author":"Ekaterina","year":"2023","journal-title":"ERJ Open Research"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0080","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.jaci.2006.12.662","article-title":"Development and cross-sectional validation of the Childhood Asthma Control Test","volume":"119","author":"Liu","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01231-2022","article-title":"Identifying and appraising outcome measures for severe asthma: a systematic review","volume":"61","author":"Rattu","year":"2023","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0090","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00691-2024","article-title":"Patient-centred composite scores as tools for assessment of response to biological therapy for paediatric and adult severe asthma","volume":"65","author":"Khaleva","year":"2025","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0095","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: what is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"preferred definitions and conceptual framework","volume":"69","author":"Biomarkers and surrogate endpoints","year":"2001","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.prrv.2026.05.009_b0110","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1111\/all.13806","article-title":"Toward clinically applicable biomarkers for asthma: an EAACI position paper","volume":"74","author":"Diamant","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.prrv.2026.05.009_b0115","first-page":"118","article-title":"Understanding the immunology of asthma: pathophysiology, biomarkers, and treatments for asthma endotypes","volume":"36","author":"Gans","year":"2020","journal-title":"Paediatr Respir Rev"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0120","article-title":"Management of the patient with eosinophilic asthma: a new era begins","volume":"1","author":"Jantina","year":"2015","journal-title":"ERJ Open Res"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0125","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0130","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.jaci.2016.09.028","article-title":"Individualized therapy for persistent asthma in young children","volume":"138","author":"Fitzpatrick","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0135","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2004.11.014","article-title":"Characterization of within-subject responses to fluticasone and montelukast in childhood asthma","volume":"115","author":"Szefler","year":"2005","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0145","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.rmed.2009.09.011","article-title":"Effect of omalizumab on peripheral blood eosinophilia in allergic asthma","volume":"104","author":"Massanari","year":"2010","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0150","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.anai.2019.11.016","article-title":"Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma","volume":"124","author":"Busse","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0155","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/pai.13484","article-title":"Omalizumab outcomes for up to 6 years in pediatric patients with severe persistent allergic asthma","volume":"32","author":"Nieto Garc\u00eda","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"issue":"13","key":"10.1016\/j.prrv.2026.05.009_b0160","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N Engl J Med"},{"issue":"10351","key":"10.1016\/j.prrv.2026.05.009_b0165","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.prrv.2026.05.009_b0175","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"9","key":"10.1016\/j.prrv.2026.05.009_b0180","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin Ther"},{"issue":"24","key":"10.1016\/j.prrv.2026.05.009_b0185","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in children with uncontrolled moderate-to-severe asthma","volume":"385","author":"Bacharier","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0190","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/all.14611","article-title":"Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline","volume":"76","author":"Bourdin","year":"2021","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.prrv.2026.05.009_b0195","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.prrv.2026.05.009_b0200","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0205","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S2213-2600(21)00322-2","article-title":"Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study","volume":"10","author":"Wechsler","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.prrv.2026.05.009_b0210","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/cea.70005","article-title":"Dupilumab efficacy and safety in patients with persistent asthma: Asia-Pacific region","volume":"55","author":"Zhang","year":"2025","journal-title":"Clin Exp Allergy"},{"issue":"10","key":"10.1016\/j.prrv.2026.05.009_b0215","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1016\/j.jaip.2022.08.006","article-title":"Dupilumab and eosinophils: a red flag?","volume":"10","author":"Busse","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10056","key":"10.1016\/j.prrv.2026.05.009_b0220","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.prrv.2026.05.009_b0225","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0230","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0235","doi-asserted-by":"crossref","DOI":"10.1111\/pai.14092","article-title":"Benralizumab in children with severe eosinophilic asthma: pharmacokinetics and long-term safety (TATE study)","volume":"35","author":"Wedner","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0240","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12931-020-01526-6","article-title":"NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0245","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1080\/02770903.2022.2082309","article-title":"One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study","volume":"60","author":"Shinkai","year":"2023","journal-title":"J Asthma"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1164\/rccm.202210-2005OC","article-title":"Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials","volume":"208","author":"Corren","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5, Supplement","key":"10.1016\/j.prrv.2026.05.009_b0255","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/j.anai.2022.08.607","article-title":"Effect of tezepelumab on asthma inflammatory biomarker levels varies by baseline biomarker levels","volume":"129","author":"Corren","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0260","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01296-2021","article-title":"The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM)","volume":"59","author":"Sverrild","year":"2022","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.prrv.2026.05.009_b0265","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S2213-2600(21)00226-5","article-title":"Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"9","author":"Diver","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0270","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"10.1016\/j.prrv.2026.05.009_b0275","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson David","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0280","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12931-020-01541-7","article-title":"DESTINATION: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the long-term safety and tolerability of tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"21","author":"Menzies-Gow","year":"2020","journal-title":"Respir Res"},{"issue":"8","key":"10.1016\/j.prrv.2026.05.009_b0285","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0290","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0295","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.aller.2014.11.004","article-title":"A pathophysiological approach for FeNO: a biomarker for asthma","volume":"43","author":"Ricciardolo","year":"2015","journal-title":"Allergol Immunopathol (Madr)"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0300","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01633-2019","article-title":"Clinical utility of fractional exhaled nitric oxide in severe asthma management","volume":"55","author":"Menzies-Gow","year":"2020","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0305","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1476-5381.2009.00374.x","article-title":"Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives","volume":"158","author":"Maarsingh","year":"2009","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0310","first-page":"36","article-title":"Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian respiratory Society (SIP\/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC)","volume":"15","author":"Heffler","year":"2020","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.prrv.2026.05.009_b0315","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5753524","article-title":"Understanding the cellular sources of the fractional exhaled nitric oxide (FeNO) and its role as a biomarker of type 2 inflammation in asthma","volume":"2022","author":"Escamilla-Gil","year":"2022","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0320","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/thoraxjnl-2016-208704","article-title":"Accuracy of FENO for diagnosing asthma: a systematic review","volume":"72","author":"Karrasch","year":"2017","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0325","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00451-2022","article-title":"Development and validation of a predictive model combining patient-reported outcome measures, spirometry and exhaled nitric oxide fraction for asthma diagnosis","volume":"9","author":"Louis","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.prrv.2026.05.009_b0330","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fped.2019.00041","article-title":"The Role of FeNO in predicting asthma","volume":"7","author":"Pijnenburg","year":"2019","journal-title":"front Pediatr"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0335","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaip.2016.08.002","article-title":"Determinants of incomplete asthma control in patients with allergic rhinitis and asthma","volume":"5","author":"Oka","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"10.1016\/j.prrv.2026.05.009_b0340","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.05.009_b0345","unstructured":"Wang, Z., et al., AHRQ Comparative Effectiveness Reviews, in The Clinical Utility of Fractional Exhaled Nitric Oxide (FeNO) in Asthma Management. 2017, Agency for Healthcare Research and Quality (US): Rockville (MD)."},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0350","article-title":"Factors influencing the concentration of exhaled nitric oxide (FeNO) in school children aged 8-9-years-old in Krakow, with High FeNO values \u226520 ppb","volume":"58","author":"Czubaj-Kowal","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0355","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1399-3038.2012.01279.x","article-title":"Exhaled NO is a poor marker of asthma control in children with a reported use of asthma medication: a pharmacy-based study","volume":"23","author":"Vijverberg","year":"2012","journal-title":"Pediatr Allergy Immunol"},{"issue":"7","key":"10.1016\/j.prrv.2026.05.009_b0360","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1016\/j.jaip.2025.04.036","article-title":"Exploring the long-term utility of remotely monitored FeNO suppression testing in severe asthma","volume":"13","author":"Busby","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0365","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1542\/peds.113.4.e308","article-title":"Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody","volume":"113","author":"Silkoff","year":"2004","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0370","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.anai.2020.09.005","article-title":"Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma: a retrospective analysis","volume":"126","author":"Ramonell","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0375","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0380","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"issue":"8","key":"10.1016\/j.prrv.2026.05.009_b0385","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/02770903.2024.2303767","article-title":"Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single center experience","volume":"61","author":"Lim","year":"2024","journal-title":"J Asthma"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0390","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/j.clinthera.2021.03.023","article-title":"Real-world effectiveness of mepolizumab in severe eosinophilic asthma: a systematic review and meta-analysis","volume":"43","author":"Li","year":"2021","journal-title":"Clin Ther"},{"issue":"8","key":"10.1016\/j.prrv.2026.05.009_b0395","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1111\/all.14872","article-title":"Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST","volume":"76","author":"Maspero","year":"2021","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0400","article-title":"Exploring the interaction between fractional exhaled nitric oxide and biologic treatment in severe asthma. A systematic review","volume":"12","author":"Pianigiani","year":"2023","journal-title":"Antioxidants (Basel)"},{"issue":"8","key":"10.1016\/j.prrv.2026.05.009_b0405","article-title":"Update on the role of FeNO in asthma management","volume":"13","author":"Murugesan","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0410","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.prrv.2026.05.009_b0415","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1009705","article-title":"Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children","volume":"364","author":"Busse","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.prrv.2026.05.009_b0420","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"suppl 66","key":"10.1016\/j.prrv.2026.05.009_b0425","first-page":"4570","article-title":"Assessment of the long-term safety and efficacy of dupilumab in children with asthma: liberty asthma excursion","volume":"60","author":"Bacharier","year":"2022","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.prrv.2026.05.009_b0430","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1080\/02770903.2025.2494233","article-title":"Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthma","volume":"62","author":"Busse","year":"2025","journal-title":"J Asthma"},{"issue":"8","key":"10.1016\/j.prrv.2026.05.009_b0435","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1111\/all.15743","article-title":"Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma","volume":"78","author":"Papadopoulos","year":"2023","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0440","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0445","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1183\/09031936.00149812","article-title":"Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey","volume":"42","author":"Deschildre","year":"2013","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0450","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1080\/02770903.2018.1553051","article-title":"Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population","volume":"57","author":"Tarraf","year":"2020","journal-title":"J Asthma"},{"issue":"13","key":"10.1016\/j.prrv.2026.05.009_b0455","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0460","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.05.009_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152379","article-title":"Patient global assessment and inflammatory markers in patients with idiopathic inflammatory myopathies \u2013 a longitudinal study","volume":"65","author":"Lodin","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0470","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00558-2023","article-title":"Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study","volume":"62","author":"Fiocchi","year":"2023","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0475","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaci.2006.02.046","article-title":"Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals","volume":"118","author":"Takayama","year":"2006","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0480","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaci.2012.06.025","article-title":"Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients","volume":"130","author":"Jia","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0485","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1164\/rccm.201403-0562LE","article-title":"Osteopontin and periostin are associated with a 20-year decline of pulmonary function in patients with asthma","volume":"190","author":"Kanemitsu","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0490","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40521-016-0106-0","article-title":"Biomarkers for the phenotyping and monitoring of asthma in children","volume":"3","author":"James","year":"2016","journal-title":"Curr Treat Options Allergy"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0495","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.alit.2014.07.003","article-title":"Phenotype of asthma related with high serum periostin levels","volume":"64","author":"Matsusaka","year":"2015","journal-title":"Allergol Int"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0500","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s42003-024-05943-x","article-title":"New perspectives on 'Breathomics': metabolomic profiling of non-volatile organic compounds in exhaled breath using DI-FT-ICR-MS","volume":"7","author":"Malik","year":"2024","journal-title":"Commun Biol"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0505","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.prrv.2007.08.007","article-title":"Indoor air quality and respiratory health of children","volume":"8","author":"Franklin","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0510","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.jaci.2007.05.043","article-title":"An electronic nose in the discrimination of patients with asthma and controls","volume":"120","author":"Dragonieri","year":"2007","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.prrv.2026.05.009_b0515","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1365-2222.2011.03800.x","article-title":"External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease","volume":"41","author":"Fens","year":"2011","journal-title":"Clin Exp Allergy"},{"issue":"11","key":"10.1016\/j.prrv.2026.05.009_b0520","first-page":"1059","article-title":"Incidence of asthma diagnosis and self-reported allergy in relation to the school environment\u2013a four-year follow-up study in schoolchildren","volume":"5","author":"Smedje","year":"2001","journal-title":"Int J Tuberc Lung Dis"},{"issue":"9","key":"10.1016\/j.prrv.2026.05.009_b0525","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/thx.2003.013680","article-title":"Association of domestic exposure to volatile organic compounds with asthma in young children","volume":"59","author":"Rumchev","year":"2004","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.prrv.2026.05.009_b0530","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/ppul.23785","article-title":"Breathomics from exhaled volatile organic compounds in pediatric asthma","volume":"52","author":"Neerincx","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"135","key":"10.1016\/j.prrv.2026.05.009_b0535","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1183\/09059180.00000714","article-title":"Volatile organic compounds and risk of asthma and allergy: a systematic review","volume":"24","author":"Nurmatov","year":"2015","journal-title":"Eur Respir Rev"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0540","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jaip.2016.11.004","article-title":"Urinary leukotriene E4 to determine aspirin intolerance in asthma: a systematic review and meta-analysis","volume":"5","author":"Hagan","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0545","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/thorax.2003.006825","article-title":"Increase in urinary leukotriene LTE4 levels in acute asthma: correlation with airflow limitation","volume":"59","author":"Green","year":"2004","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0550","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11060484","article-title":"A system pharmacology multi-omics approach toward uncontrolled pediatric asthma","volume":"11","author":"Abdel-Aziz","year":"2021","journal-title":"J Pers Med"},{"issue":"10","key":"10.1016\/j.prrv.2026.05.009_b0555","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/all.15412","article-title":"Omics technologies in allergy and asthma research: an EAACI position paper","volume":"77","author":"Radzikowska","year":"2022","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0560","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1183\/13993003.00780-2015","article-title":"The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts","volume":"46","author":"Fleming","year":"2015","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0565","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jaip.2017.05.032","article-title":"Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age","volume":"6","author":"Teague","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.prrv.2026.05.009_b0570","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1008142","article-title":"An integrative association method for omics data based on a modified Fisher's method with application to childhood asthma","volume":"15","author":"Yan","year":"2019","journal-title":"PLoS Genet"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0575","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaci.2019.02.032","article-title":"Integrative analysis of the intestinal metabolome of childhood asthma","volume":"144","author":"Lee-Sarwar","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.prrv.2026.05.009_b0580","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01193-2022","article-title":"Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma","volume":"61","author":"Gauvreau","year":"2023","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2026.05.009_b0585","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.coi.2014.09.004","article-title":"IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy","volume":"31","author":"Cayrol","year":"2014","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0590","doi-asserted-by":"crossref","first-page":"9825","DOI":"10.1038\/s41598-023-36642-y","article-title":"Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE\/EGFR to reduce inflammation and epithelial dysfunction","volume":"13","author":"England","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.prrv.2026.05.009_b0595","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMoa1106469","article-title":"Lebrikizumab treatment in adults with asthma","volume":"365","author":"Corren","year":"2011","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.prrv.2026.05.009_b0600","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/S2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0605","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01461-2024","article-title":"A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule","volume":"65","author":"Deiteren","year":"2025","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0610","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-world experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0615","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.anai.2023.11.006","article-title":"Real-world effectiveness of dupilumab in patients with asthma: Findings from the US ADVANTAGE study","volume":"132","author":"Blaiss","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"10.1016\/j.prrv.2026.05.009_b0620","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.rmed.2009.06.014","article-title":"\u201cReal-life\u201d effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study","volume":"103","author":"Brusselle","year":"2009","journal-title":"Respir Med"},{"key":"10.1016\/j.prrv.2026.05.009_b0625","unstructured":"(CASAM), S.f.C.A.W.S.A.W.a.E.P.T.W.M. CASAM. [cited 2024; Available from: https:\/\/clinicaltrials.gov\/study\/NCT05139381?cond=Asthma&term=CHILDREN%20or%20adolescent&intr=Mepolizumab&rank=1#publications."},{"key":"10.1016\/j.prrv.2026.05.009_b0630","unstructured":"Clinicaltrials.gov. Tezepelumab. Available from: https:\/\/clinicaltrials.gov\/search?cond=Asthma&intr=TEZEPELUMAB."},{"key":"10.1016\/j.prrv.2026.05.009_b0635","unstructured":"(PANDA), P.o.A.E.U.D.i.U.C.a.A. [cited 2024; Available from: https:\/\/clinicaltrials.gov\/study\/NCT05347771?cond=Asthma&term=CHILDREN%20or%20adolescent&intr=Dupilumab&rank=1."},{"key":"10.1016\/j.prrv.2026.05.009_b0640","unstructured":"(RAPID), R.o.A.P.I.D. [cited 2024; Available from: https:\/\/clinicaltrials.gov\/study\/NCT04287621?cond=Asthma&intr=Dupilumab&term=rapid&rank=1."},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0645","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/j.jaci.2024.07.029","article-title":"Comparative effectiveness of dupilumab and omalizumab on asthma exacerbations and systemic corticosteroid prescriptions: Real-world US ADVANTAGE study","volume":"154","author":"Bleecker","year":"2024","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.prrv.2026.05.009_b0650","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-2600(19)30045-1","article-title":"Biologics for paediatric severe asthma: trick or TREAT?","volume":"7","author":"Saglani","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.prrv.2026.05.009_b0655","first-page":"00709","article-title":"Severe Paediatric Asthma Collaborative in Europe: real world data on children on biologics","author":"Liu","year":"2025","journal-title":"ERJ Open Research"},{"key":"10.1016\/j.prrv.2026.05.009_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2020.106228","article-title":"Preventing asthma in high risk kids (PARK) with omalizumab: Design, rationale, methods, lessons learned and adaptation","volume":"100","author":"Phipatanakul","year":"2021","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0665","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1183\/09031936.00010712","article-title":"Exhaled volatile organic compounds predict exacerbations of childhood asthma in a 1-year prospective study","volume":"42","author":"Robroeks","year":"2013","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.prrv.2026.05.009_b0670","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1016\/j.jaip.2021.02.031","article-title":"Asthma patients who stop asthma biologics have a similar risk of asthma exacerbations as those who continue asthma biologics","volume":"9","author":"Jeffery","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0675","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00819-2023","article-title":"Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry","volume":"62","author":"McDowell","year":"2023","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0680","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","article-title":"Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment","volume":"131","author":"Blaiss","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.prrv.2026.05.009_b0685","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arbres.2024.04.002","article-title":"Spanish Consensus on Remission in Asthma (REMAS)","volume":"60","author":"\u00c1lvarez-Guti\u00e9rrez","year":"2024","journal-title":"Archivos de Bronconeumolog\u00eda"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0690","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.chest.2023.10.046","article-title":"Clinical response and remission in patients with severe asthma treated with biologic therapies","volume":"165","author":"Hansen","year":"2024","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.prrv.2026.05.009_b0695","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.alit.2025.11.004","article-title":"Consensus definition of clinical remission in asthma for the Japanese asthma prevention and management guidelines (JGL 2024): a modified Delphi survey and comprehensive review","volume":"75","author":"Nagase","year":"2026","journal-title":"Allergol Int"},{"issue":"2","key":"10.1016\/j.prrv.2026.05.009_b0700","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1542\/peds.108.2.e36","article-title":"Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)","volume":"108","author":"Milgrom","year":"2001","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.prrv.2026.05.009_b0705","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jaci.2009.09.021","article-title":"Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma","volume":"124","author":"Lanier","year":"2009","journal-title":"J Allergy Clin Immunol"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054226000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T19:17:50Z","timestamp":1781983070000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054226000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":141,"alternative-id":["S1526054226000527"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2026.05.009","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to monitor response to biologics in children with severe asthma","name":"articletitle","label":"Article Title"},{"value":"Paediatric Respiratory Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prrv.2026.05.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}